Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ultragenyx Pharmaceu (NQ: RARE ) 50.99 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 680,606 Open 51.14 Bid (Size) 45.00 (3) Ask (Size) 57.29 (20) Prev. Close 50.99 Today's Range 50.83 - 51.84 52wk Range 34.06 - 60.37 Shares Outstanding 70,814,462 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update October 29, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Decoding 10 Analyst Evaluations For Ultragenyx Pharmaceutical October 21, 2024 Via Benzinga Performance YTD +5.85% +5.85% 1 Month -5.21% -5.21% 3 Month +3.89% +3.89% 6 Month +18.55% +18.55% 1 Year +34.93% +34.93% More News Read More Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) October 18, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta October 07, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Breaking Down Ultragenyx Pharmaceutical: 10 Analysts Share Their Views September 20, 2024 Via Benzinga Unveiling 14 Analyst Insights On Ultragenyx Pharmaceutical July 22, 2024 Via Benzinga Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease October 03, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting September 26, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) September 18, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx to Participate in Investor Conferences in September August 29, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) August 21, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs August 06, 2024 Via Benzinga Topics Lawsuit Exposures Financial Legal 3 Genomics Stocks That May Transform Personalized Medicine August 06, 2024 Via InvestorPlace Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update August 01, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update July 25, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium July 24, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst July 22, 2024 Via Benzinga Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong July 22, 2024 Via Investor's Business Daily Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) July 19, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program July 17, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) June 20, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire 7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline June 17, 2024 Via InvestorPlace Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session June 14, 2024 Via Benzinga Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants June 13, 2024 From Ultragenyx Pharmaceutical Inc. Via GlobeNewswire Dave & Buster's Posts Downbeat Results, Joins J.Jill And Other Big Stocks Moving Lower In Thursday's Pre-Market Session June 13, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
